Is Cerebral profitable in 2026?

There is no public evidence of profitability. Cerebral's revenue figures are unverified aggregator estimates, with Getlatka citing $225M for 2025, but no audited financials exist since it is private and has raised only $25M since 2021, tied to acquisitions rather than organic growth.

Has Cerebral had layoffs?

Yes. Cerebral cut 20% of staff in October 2022, then 15% more (about 285 employees) in February 2023, its third round within a year. Revelio Labs estimates headcount fell 42.2%, from 1,272 in 2023 to 736 by Q1 2026.

Who is Cerebral's biggest competitor?

Talkiatry, Grow Therapy, and Brightside Health compete directly on insurance-based psychiatry and therapy without Cerebral's regulatory baggage, while Teladoc, Amwell, and MDLive bundle behavioral health into larger telehealth platforms, per sector coverage as of June 2026.

Could AI replace Cerebral's services?

AI chatbots and apps can increasingly handle intake triage, symptom screening, and CBT-style psychoeducation, the low-acuity tier of Cerebral's funnel. But DEA-licensed prescribing authority and existing payer contracts with Aetna, Cigna, and UnitedHealthcare remain harder for AI-only platforms to replicate as of 2026.

Who owns Cerebral and what is it worth?

Cerebral is privately held and VC-backed with no parent company. Its last confirmed valuation was $4.8B from a SoftBank Vision Fund 2 led Series C on December 8, 2021; no new priced round has occurred since, despite a smaller $25M raise in September 2025.

What legal trouble has Cerebral faced?

Cerebral paid a $7.1M FTC settlement in April 2024 over deceptive health-data practices, completed over $5M in consumer refunds by May 2025, and settled a separate $500K Meta Pixel data-sharing class action with distribution around June 22, 2026. Founder Kyle Robertson still faces a pending personal FTC action in Florida.

United States · United States

Cerebral

Online psychiatry and therapy platform serving insured patients by video and app.

Little protection left

Assessed 29 July 2026 · Evidence as of 29 July 2026

Not much stands between this business and its pressures.

On the recordSince 29 July 2026 · Checkable from June 22, 2026 · Every call on the record Checkpoint: FTC settlement finalization and distribution over Cerebral's marketing and prescribing practices

The call

Cerebral lost the fast-prescribing wedge that built it and now competes as one insurance-based therapy option among many, with its valuation unchanged since 2021 and headcount still shrinking.

Cerebral connects patients with therapists and psychiatrists online, originally by making it easy to get prescription medications fast. When the government cracked down on that approach in 2022, Cerebral was left running a basic telehealth psychiatry service that companies like Talkiatry and Grow Therapy already do better, and without the legal problems. Bigger players like Teladoc and Optum have already folded therapy into their larger health platforms, while AI chatbots are starting to handle simpler mental health tasks that used to need a doctor visit. The one thing that could change the picture is if Cerebral's new focus on working with insurance companies actually starts gaining real traction instead of just cutting costs.

Why

AI pressure: AI-driven intake triage and CBT chatbot tools. AI triage and chatbot tools are starting to handle low-acuity mental health intake, the same funnel Cerebral relies on. Could AI do the core job? Yes, likely.

Bigger players: Teladoc Health, Amwell, and Optum/Evernorth behavioral health. Bundled telehealth platforms and payer-owned behavioral health units already offer psychiatry and therapy inside plans Cerebral must bill through. Could a giant copy it? Yes, easily.

What protects it. A base of over a million past patients and thousands of contracted clinicians it can still bill against, even without its original prescribing wedge.

What would change this call

Cerebral announces a new priced funding round, sale, or wind-down within 12 months. Shows whether investors still value the company beyond bridge financing.
Resolution of the FTC case against founder Kyle Robertson. Shows whether legal exposure keeps weighing on the brand and leadership.
Headcount trend past the 2026 low of ~12 job postings reverses or continues falling. Indicates whether the 'Cerebral 2.0' pivot is stabilizing or still shrinking.

Key numbers

$300M Series C at $4.8B valuation (2021-12-08)
20% staff layoff following DOJ/FTC scrutiny (2022-10-24)
$25M raised, first new capital since 2021 (2025-09-12)

Named risks

Founder Kyle Robertson faces pending personal FTC enforcement action in Florida federal court. Severity: high
No priced equity round since December 2021, valuation of $4.8B is nearly five years stale. Severity: high
Headcount decline of over 40% since 2023 signals shrinking operational scale. Severity: medium
Revenue figures across aggregators are inconsistent and unverified by audited filings. Severity: medium
Low-acuity funnel (triage, CBT modules) increasingly replicable by AI chatbots and apps. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Talkiatry	losing to	Insurance-based psychiatry model without Cerebral's DOJ/FTC regulatory baggage, as of 2026
Grow Therapy	losing to	Direct insurance-billing therapy competitor gaining share as Cerebral shrinks, 2026
Brightside Health	losing to	Specialized psychiatry and therapy competitor cited among top peer alternatives, June 2026
Teladoc Health	contesting	Bundles behavioral health within broader telehealth platform, competing for same funnel
Optum/Evernorth	gaining on	Plans to triple behavioral health provider count and expand to all 50 states in 2026
BetterHelp	contesting	Faced its own $7.8M FTC data-sharing action in 2023, sharing regulatory risk with Cerebral

Questions people ask

Is Cerebral profitable in 2026?: There is no public evidence of profitability. Cerebral's revenue figures are unverified aggregator estimates, with Getlatka citing $225M for 2025, but no audited financials exist since it is private and has raised only $25M since 2021, tied to acquisitions rather than organic growth.
Has Cerebral had layoffs?: Yes. Cerebral cut 20% of staff in October 2022, then 15% more (about 285 employees) in February 2023, its third round within a year. Revelio Labs estimates headcount fell 42.2%, from 1,272 in 2023 to 736 by Q1 2026.
Who is Cerebral's biggest competitor?: Talkiatry, Grow Therapy, and Brightside Health compete directly on insurance-based psychiatry and therapy without Cerebral's regulatory baggage, while Teladoc, Amwell, and MDLive bundle behavioral health into larger telehealth platforms, per sector coverage as of June 2026.
Could AI replace Cerebral's services?: AI chatbots and apps can increasingly handle intake triage, symptom screening, and CBT-style psychoeducation, the low-acuity tier of Cerebral's funnel. But DEA-licensed prescribing authority and existing payer contracts with Aetna, Cigna, and UnitedHealthcare remain harder for AI-only platforms to replicate as of 2026.
Who owns Cerebral and what is it worth?: Cerebral is privately held and VC-backed with no parent company. Its last confirmed valuation was $4.8B from a SoftBank Vision Fund 2 led Series C on December 8, 2021; no new priced round has occurred since, despite a smaller $25M raise in September 2025.
What legal trouble has Cerebral faced?: Cerebral paid a $7.1M FTC settlement in April 2024 over deceptive health-data practices, completed over $5M in consumer refunds by May 2025, and settled a separate $500K Meta Pixel data-sharing class action with distribution around June 22, 2026. Founder Kyle Robertson still faces a pending personal FTC action in Florida.

Timeline

2026-03-24Cerebral acquires CBT-based ADHD app Inflow, partial ADHD reentry without stimulant prescribing
2025-12-09Cerebral settles $500K Meta Pixel data-sharing class action, final hearing set for March 2026
2025-09-12Cerebral raises $25M, first capital raise since 2021, tied to M&A strategy
2025-08-05Cerebral makes first acquisition, buys Resilience Lab for clinical quality
2025-05-08FTC completes over $5M in consumer refunds tied to 2024 data settlement
2025-03-05CEO David Mou steps down to found new venture; Brian Reinken becomes interim CEO
2024-04-17Cerebral agrees to $7.1M FTC settlement over deceptive health-data practices
2023-02-28Cerebral lays off 15% of staff, third round of cuts within a year
2022-10-24Cerebral lays off 20% of staff for operational efficiencies
2021-12-08SoftBank Vision Fund 2 leads $300M Series C at $4.8B valuation

Revision history

29 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Warner Bros. Discovery Inflection AI Story Protocol